started · updated
Moderna reports $1.31 billion in Q3 2026 revenue and returns to profitability
Moderna has reported third-quarter 2026 financial results, achieving total consolidated revenue of $1.31 billion. This represents a 29% increase compared to the $1.016 billion reported in the same period the previous year. The biotechnology company returned to profitability with a net profit of $162 million, reversing a net loss of $200 million recorded in the third quarter of 2025.
Key financial metrics include a GAAP diluted earnings per share (EPS) of $0.38, significantly exceeding analyst expectations. The company's revenue growth was primarily driven by international demand for COVID-19 vaccines supported by government supply agreements. Consequently, Moderna has raised its annual revenue projections to a range of 15% to 25% for the close of 2026.
Other factors influencing market sentiment include the WHO advisory group's recommendation to include Moderna's Ebola vaccine candidate, mRNA-1469, in Phase 2/3 trials in the Democratic Republic of the Congo. Additionally, the company announced it would present preliminary data on its investigational mRNA therapy for multiple myeloma at an upcoming oncology conference.
Entities
Democratic Republic of the Congo · Merck · Moderna · Nasdaq · World Health Organization
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 2 SOURCES] GAAP diluted earnings per share was $0.38. bitfinanzas.com · stockstory.org
- [○ 1 SOURCE] Intismeran combined with Merck's Keytruda showed a 42% lower relative risk of melanoma recurrence or death in published findings. www.financial-news.co.uk
- [○ 1 SOURCE] Moderna recorded a net profit of $162 million in Q3 2026. bitfinanzas.com
- [● 2 SOURCES] Moderna reported Q3 2026 revenue of $1.31 billion. bitfinanzas.com · stockstory.org
- [○ 1 SOURCE] Moderna raised annual revenue projections to a range of 15% to 25% for the end of 2026. bitfinanzas.com
- [● 2 SOURCES] Revenue increased by 29% year-on-year. bitfinanzas.com · stockstory.org
- [○ 1 SOURCE] The WHO advisory group recommended Moderna's Ebola vaccine candidate, mRNA-1469, be included in a Phase 2/3 trial in the Democratic Republic of the Congo. www.financial-news.co.uk
- [○ 1 SOURCE] Moderna's stock rose 13% in a single session on November 4. www.financial-news.co.uk